Materias dentro de su búsqueda.
Mostrando 484,601 - 484,620 Resultados de 487,202 Para Buscar '"free will"', tiempo de consulta: 2.13s Limitar resultados
  1. 484601
    “…Univariate and multivariate analyses were conducted to recognize independent factors associated with overall survival (OS) and disease-free survival (DFS). The nomogram aimed to predict the 1-, 3- and 5-year survival probabilities. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma
  2. 484602
    “…The survey was conducted online through a questionnaire including the possibility for free text entry, and concentrated on the following topics: 1. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Malaria vector control tools in emergency settings: What do experts think? Results from a DELPHI survey
  3. 484603
    “…METHODS: This study enrolled patients with coexisting malignancy and tuberculosis and treated with anti-PD-(L)1 from Jan 2018 to July 2021 in 2 institutions. The progression-free survival (PFS), objective response rate (ORR), and safety of anti-PD-(L)1 therapy, as well as response to anti-tuberculosis treatment, were evaluated. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage
  4. 484604
    “…The satisfaction rate was 69% (117/169), and the overall pain-free survival rate was 68%, without any significant difference between arthritic grades. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Long-term Follow-up of Cheilectomy for Treatment of Hallux Rigidus
  5. 484605
    “…Images were analysed for thigh fat‐tissue free muscle volume and muscle fat infiltration (MFI) using AMRA® Researcher (AMRA Medical, Linköping, Sweden). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Adverse muscle composition predicts all‐cause mortality in the UK Biobank imaging study
  6. 484606
    “…During the follow-up period, 13 of 216 patients (6.0%) died (12 infections and one senility), and 76 of 216 patients (35.1%) experienced relapses. Overall and relapse-free survival rates at 5 years were 94.9% and 57.3%, respectively, and those rates were not significantly different between Class 1 and 2 (p=0.30 and p=0.19). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Latent class analysis of 216 patients with adult-onset Still’s disease
  7. 484607
    “…This applies especially to anti-citrullinated protein antibodies (ACPA)-negative RA, where a proportion achieves sustained DMARD-free remission (SDFR; sustained absence of synovitis after DMARD cessation). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution
  8. 484608
    “…RESULTS: The median overall survival (OS) and progression-free survival (PFS) were 33.0 months and 24.0 months, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Optimizing the treatment mode for de novo metastatic nasopharyngeal carcinoma with bone-only metastasis
  9. 484609
    “…METHODS: A prospective study of Danish patients hospitalized with CAP caused by SARS-CoV-2, influenza, or bacteria. Fat (FM) and fat-free mass (FFM) were assessed with bioelectrical impedance analysis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Body composition, physical capacity, and immuno-metabolic profile in community-acquired pneumonia caused by COVID-19, influenza, and bacteria: a prospective cohort study
  10. 484610
    “…IMPORTANCE: Prospective evidence suggests abiraterone is associated with superior progression-free survival for African American men compared with non-Hispanic White men with metastatic castration-resistant prostate cancer (mCRPC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone
  11. 484611
    “…We report the safety outcomes (safety analysis set, Parts 1 and 2 combined) along with the primary (progression-free survival (PFS)) and secondary (overall survival (OS)) efficacy endpoints. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
  12. 484612
    “…Across archetypes, participants indicated a willingness to comply with cannabis policies which are simple and easy to understand, which do not lead to discrimination or law enforcement involvement, and which provide for legal places to purchase and use safe (i.e., free of adulterants) cannabis products. CONCLUSIONS: We posit that these archetypes could be useful to inform cannabis policy design. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Identifying archetypal cannabis consumers to inform drug policy design: a Q-sort assessment of young adults’ attitudes in Mexico City’s metropolitan area
  13. 484613
    “…The primary endpoint was the overall survival (OS), and the secondary endpoints included the progression-free survival (PFS), objective response rate (ORR), toxicities, and treatment delivery. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data
  14. 484614
    por Rimbach, Rebecca, Yamada, Yosuke, Sagayama, Hiroyuki, Ainslie, Philip N., Anderson, Lene F., Anderson, Liam J., Arab, Lenore, Baddou, Issaad, Bedu-Addo, Kweku, Blaak, Ellen E., Blanc, Stephane, Bonomi, Alberto G., Bouten, Carlijn V. C., Bovet, Pascal, Buchowski, Maciej S., Butte, Nancy F., Camps, Stefan G. J. A., Close, Graeme L., Cooper, Jamie A., Das, Sai Krupa, Dugas, Lara R., Ekelund, Ulf, Entringer, Sonja, Forrester, Terrence, Fudge, Barry W., Goris, Annelies H., Gurven, Michael, Hambly, Catherine, El Hamdouchi, Asmaa, Hoos, Marije B., Hu, Sumei, Joonas, Noorjehan, Joosen, Annemiek M., Katzmarzyk, Peter, Kempen, Kitty P., Kimura, Misaka, Kraus, William E., Kushner, Robert F., Lambert, Estelle V., Leonard, William R., Lessan, Nader, Martin, Corby K., Medin, Anine C., Meijer, Erwin P., Morehen, James C., Morton, James P., Neuhouser, Marian L., Nicklas, Theresa A., Ojiambo, Robert M., Pietiläinen, Kirsi H., Pitsiladis, Yannis P., Plange-Rhule, Jacob, Plasqui, Guy, Prentice, Ross L., Rabinovich, Roberto A., Racette, Susan B., Raichlen, David A., Ravussin, Eric, Reynolds, Rebecca M., Roberts, Susan B., Schuit, Albertine J., Sjödin, Anders M., Stice, Eric, Urlacher, Samuel S., Valenti, Giulio, Van Etten, Ludo M., Van Mil, Edgar A., Wells, Jonathan C. K., Wilson, George, Wood, Brian M., Yanovski, Jack, Yoshida, Tsukasa, Zhang, Xueying, Murphy-Alford, Alexia J., Loechl, Cornelia U., Luke, Amy H., Rood, Jennifer, Schoeller, Dale A., Westerterp, Klaas R., Wong, William W., Speakman, John R., Pontzer, Herman
    Publicado 2022
    “…We examine repeated doubly labeled water (DLW) measurements of TEE in 348 adults and 47 children from the IAEA DLW Database (mean ± SD time interval: 1.9 ± 2.9 y) to assess repeatability of TEE, and to examine if TEE adjusted for age, sex, fat-free mass, and fat mass is associated with changes in weight or body composition. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Total energy expenditure is repeatable in adults but not associated with short-term changes in body composition
  15. 484615
    “…Kaplan–Meier analyses were used to calculate progression-free (PFS) and overall survival (OS), influencing variables were evaluated using Cox-regression analyses. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study
  16. 484616
    por Mauro, Francesca Romana, Paoloni, Francesca, Molica, Stefano, Reda, Gianluigi, Trentin, Livio, Sportoletti, Paolo, Marchetti, Monia, Pietrasanta, Daniela, Marasca, Roberto, Gaidano, Gianluca, Coscia, Marta, Stelitano, Caterina, Mannina, Donato, Di Renzo, Nicola, Ilariucci, Fiorella, Liberati, Anna Marina, Orsucci, Lorella, Re, Francesca, Tani, Monica, Musuraca, Gerardo, Gottardi, Daniela, Zinzani, Pier Luigi, Gozzetti, Alessandro, Molinari, Annalia, Gentile, Massimo, Chiarenza, Annalisa, Laurenti, Luca, Varettoni, Marzia, Ibatici, Adalberto, Murru, Roberta, Ruocco, Valeria, Del Giudice, Ilaria, De Propris, Maria Stefania, Della Starza, Irene, Raponi, Sara, Nanni, Mauro, Fazi, Paola, Neri, Antonino, Guarini, Anna, Rigolin, Gian Matteo, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin
    Publicado 2021
    “…Patients who discontinued ibrutinib due to an AE showed a 24-month next treatment-free survival rate of 63%. In conclusion, ibrutinib and rituximab combination was an effective front-line treatment with sustained disease control in more than half of unfit patients with CLL. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
  17. 484617
    por Wieduwilt, Matthew J., Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David I., Al-Homsi, A. Samer, Muffly, Lori, Chao, Nelson, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M., Cairo, Mitchell, Mussetti, Alberto, Gore, Steven, Bhatt, Vijaya Raj, Patel, Sagar S., Michelis, Fotios V., Inamoto, Yoshihiro, Badawy, Sherif M., Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Ganguly, Siddhartha, Bredeson, Christopher, Diaz Perez, Miguel Angel, Cassaday, Ryan, Savani, Bipin N., Ballen, Karen, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S., Yared, Jean A., Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K., Solh, Melhem, Seftel, Matthew D., van der Poel, Marjolein, Grunwald, Michael R., Liesveld, Jane L., Kamble, Rammurti T., McGuirk, Joseph, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, César O., Krem, Maxwell M., Winestone, Lena E., Gergis, Usama, Nathan, Sunita, Olsson, Richard F., Verdonck, Leo F., Sharma, Akshay, Ringdén, Olle, Friend, Brian D., Cerny, Jan, Choe, Hannah, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C., de Lima, Marcos, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Abid, Muhammad Bilal, Weisdorf, Daniel J., Saber, Wael
    Publicado 2022
    “…Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
  18. 484618
    “…Secondary endpoints included disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), overall survival (OS), 12-month OS rate and safety profile. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
  19. 484619
    “…Qualitative data included focus groups with staff and stakeholders, program documents, and free-text survey responses. RESULTS: All three program activity domains (multidisciplinary supports, tenant engagement, staff capacity-building) were successfully implemented. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Delivering collaborative mental health care within supportive housing: implementation evaluation of a community-hospital partnership
  20. 484620
    “…SUV(apex), a hybrid metric of SUV(max) and SUV(peak), was proposed for robust, accurate, and segmentation-free quantitation of lesions for PSMA PET. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40658-021-00429-9.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Quantitative evaluation of PSMA PET imaging using a realistic anthropomorphic phantom and shell-less radioactive epoxy lesions
Herramientas de búsqueda: RSS